FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 663 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR 10 Tips for National Cancer Prevention Month February 10, 2021 ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... June 12, 2026 Antibody Drug Ejects Problematic Proteins from Cancer Cells December 13, 2023 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 Load more HOT NEWS Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... EMA Recommends Extension of Therapeutic Indications for Nivolumab Five Questions With…Jae.
